We are excited to announce the release of the June 2026 Quick Access Files, which now include the June 1, 2026, CLARiTI data freeze. This milestone represents the tremendous effort of site teams, clinicians, coordinators, and data management staff across the consortium to recruit participants, complete study procedures, and ensure high-quality data. Thanks to your dedication, CLARiTI has reached an important stage where these data can begin supporting scientific discovery. The June 2026 freeze is now available to researchers everywhere. Please follow the standard Data Request Process to access those datasets.
Your center’s freeze data for June 2026 is also now available through the ADRC Portal. Instructions for accessing this data can be found in the EDC Docs: Center Freeze Data Download Guide. Looking ahead, NACC plans to make each site's CLARiTI data directly available through the ADRC Portal later this year, further expanding access and opportunities for local data exploration and research.
If you have any questions or concerns regarding your center’s freeze data, please submit a NACC Support Request.
The Alzheimer's Association has released the 2026 Alzheimer's Disease Facts and Figures report, featuring the latest statistics on Alzheimer's disease and related dementias in the United States. This annual resource also includes a special report on brain health and provides valuable context for researchers, clinicians, and the broader AD/ADRD community.
NLM Workshop on Data Governance and Social Challenges to Sharing Clinical Data for Research
July 13-14, 2026
This workshop will convene leaders and practitioners to compare how different clinical data sharing models handle data governance and protections, surface the most consequential barriers limiting data sharing today, and identify high-impact opportunities where the National Library of Medicine can play a strategic role in enabling responsible clinical data sharing for whole human health research.
NACC has released version 0.6.0 of the Error Report (Issue Manager), introducing several usability improvements to streamline the alert review process. Updates include customizable table settings, full error messages, one-click selection of approved visits, saved user settings, simplified alerts, and improved submission feedback to confirm successful submissions. Make sure to clear your browser cache before accessing the updated Issue Manager. For more details, see the updated Alert Verification process documentation or the ADRC Community Forum.
Strategic Data Management Roadmap
New updates include Spanish C2T forms and acceptance of UDSv4 Down Syndrome data. The Roadmap provides a centralized view of progress across NACC’s data and technology initiatives.
Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN): Powering the Next Generation of Research
Letter of Intent Deadline: July 30, 2026, 5 pm ET
Award Amount: Up to $250,000 (bridge funding spans 3–12 months)
The Alzheimer's Association and The Michael J. Fox Foundation, in partnership with the Robertson Foundation, offer bridge support for early-career investigators whose federally funded research on Alzheimer's, Parkinson's, or related neurodegenerative disorders has been disrupted. Funds cover salary and direct research costs. Open to Early Stage Investigators or those within seven years of ESI designation who can document a qualifying disruption.
BrightFocus Alzheimer's Disease Research: Postdoctoral Fellowship Award
Full Application Deadline: September 1, 2026, 5 pmET Award Amount: $200,000 over two years
BrightFocus Foundation invites applications from postdoctoral researchers for its Alzheimer's Disease Research Postdoctoral Fellowship, supporting scientists in their final stages of mentored training toward an independent research career in AD/ADRD. Applicants must be within 5 years of degree conferral. Open to U.S. and international researchers; applications from underrepresented groups are strongly encouraged; no letter of intent required.
BrightFocus Alzheimer's Disease Research: Standard Award
Application Deadline: September 1, 2026, 5 pm ET
Award Amount: Up to $300,000 over three years ($100,000 per year)
BrightFocus Foundation invites applications for its Alzheimer's Disease Research Standard Award, which funds innovative research in Alzheimer's disease and related dementias. Two tracks are available: Early Career Investigator (within 15 years of degree) and Independent Investigator, which prioritizes interdisciplinary approaches and researchers new to the Alzheimer's field. Open to U.S. and international researchers; no letter of intent required.
ADDF Neuroimaging and CSF Biomarker Program: Development and Validation of Biomarkers for Alzheimer's Disease and Related Dementias
Letter of Intent Deadline: September 14, 2026, 5 pm ET
Award Amount: Up to $600,000 based on stage and scope of research
The Alzheimer's Drug Discovery Foundation invites applications to develop and validate neuroimaging and CSF biomarkers for Alzheimer's disease and related dementias, prioritizing targets such as neuroinflammation, synaptic integrity, and TDP-43 across PET, CSF, MRI, and EEG modalities. Open to researchers and clinicians worldwide at academic institutions and nonprofits; awards cover one year of direct costs with follow-on funding potential.
NACC is funded by the National Institute on Aging (U24 AG072122) and is located in the Department of Epidemiology at the University of Washington School of Public Health, Kari A. Stephens, PhD, Director.
